SCHEMBL647464

SCHEMBL647464

COC(OC)c1cccc(O)n1

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 1/20 0.36
KMT2A Q03164 4/20 0.36
MAPT P10636 4/20 0.36
PGK1 P00558 2/20 0.34
PGK2 P07205 2/20 0.34
L3MBTL1 Q9Y468 4/20 0.34
POLB P06746 1/20 0.34
CA12 O43570 2/20 0.33
CA1 P00915 2/20 0.33
CA2 P00918 2/20 0.33
CA7 P43166 2/20 0.33
CA9 Q16790 2/20 0.33
CA14 Q9ULX7 2/20 0.33
RAB9A P51151 1/20 0.33
ALDH1A1 P00352 2/20 0.31
MAPK1 P28482 2/20 0.31
KDM4E B2RXH2 1/20 0.30
LMNA P02545 1/20 0.30
TP53 P04637 1/20 0.30
CYP3A4 P08684 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6984258 0.81
SCHEMBL9356164 0.76 CYP1A2 (0.39) SMN1; SMN2KMT2AMAPTL3MBTL1RAB9A
SCHEMBL4752882 0.76 GABRA1 (0.41) SMN1; SMN2MAPTPGK1PGK2CA1
SCHEMBL647463 0.75 SMN1; SMN2 (0.36) SMN1; SMN2KMT2AMAPTPGK1PGK2
SCHEMBL1555528 0.75 IRAK4 (0.43) SMN1; SMN2KMT2AMAPTL3MBTL1POLB
SCHEMBL29834964 0.75 IRAK4 (0.43) SMN1; SMN2KMT2AMAPTL3MBTL1POLB
SCHEMBL6831104 0.75 KDM4E (0.57) KMT2AMAPTL3MBTL1CA12CA1
SCHEMBL29955779 0.75 L3MBTL1 (0.35) SMN1; SMN2KMT2AMAPTL3MBTL1POLB
SCHEMBL6826133 0.73 MAPT (0.49) SMN1; SMN2MAPTL3MBTL1CA12CA1
SCHEMBL25864526 0.73 PGK1 (0.39) MAPTPGK1PGK2POLBALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8119563-B2 N-substituted azacycles FMC CORPORATION (US) 2012-02-21 US claimed
US-20090215821-A1 N-Substituted Azacycles FMC CORPORATION 2009-08-27 US claimed
EP-1673083-A4 N-SUBSTITUTED AZACYCLES BAYER CROPSCIENCE AG (DE) 2008-12-17 EP claimed
EP-1673083-A2 N-SUBSTITUTED AZACYCLES FMC CORPORATION (US) 2006-06-28 EP claimed
WO-2005036961-A2 N-SUBSTITUTED AZACYCLES FMC CORPORATION (US) 2005-04-28 WO claimed
US-8119563-B2 N-substituted azacycles FMC CORPORATION (US) 2012-02-21 US disclosed
US-20090215821-A1 N-Substituted Azacycles FMC CORPORATION 2009-08-27 US disclosed
EP-1673083-A4 N-SUBSTITUTED AZACYCLES BAYER CROPSCIENCE AG (DE) 2008-12-17 EP disclosed
EP-1673083-A2 N-SUBSTITUTED AZACYCLES FMC CORPORATION (US) 2006-06-28 EP disclosed
WO-2005036961-A2 N-SUBSTITUTED AZACYCLES FMC CORPORATION (US) 2005-04-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090215821-A1 N-Substituted Azacycles DDT, UQCRB, DNMT1 SMN1; SMN2 1753/4885KMT2A 1219/4885MAPT 4642/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.